M Weil

465 total citations
37 papers, 340 citations indexed

About

M Weil is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, M Weil has authored 37 papers receiving a total of 340 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 10 papers in Oncology and 9 papers in Molecular Biology. Recurrent topics in M Weil's work include Lung Cancer Treatments and Mutations (7 papers), Acute Myeloid Leukemia Research (6 papers) and Melanoma and MAPK Pathways (4 papers). M Weil is often cited by papers focused on Lung Cancer Treatments and Mutations (7 papers), Acute Myeloid Leukemia Research (6 papers) and Melanoma and MAPK Pathways (4 papers). M Weil collaborates with scholars based in France and United States. M Weil's co-authors include D. Khayat, C Jacquillat, C Jacquillat, C. Soubrane, Jean-Pierre Bizzari, Pierre Banzet, J.M. Andrieu, S Visonneau, J.M. Tourani and Kheïra Beldjord and has published in prestigious journals such as Blood, The Journal of Infectious Diseases and European Journal of Cancer.

In The Last Decade

M Weil

36 papers receiving 321 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M Weil France 10 129 114 91 72 68 37 340
Mitchell Ms United States 10 177 1.4× 107 0.9× 151 1.7× 60 0.8× 20 0.3× 21 415
D. H. Cowan Canada 12 118 0.9× 100 0.9× 67 0.7× 24 0.3× 61 0.9× 32 415
Bond Vp United States 9 81 0.6× 110 1.0× 43 0.5× 68 0.9× 47 0.7× 19 392
Johannes Mejer Denmark 10 179 1.4× 122 1.1× 59 0.6× 50 0.7× 27 0.4× 29 397
Paul L. Romain United States 10 55 0.4× 93 0.8× 220 2.4× 31 0.4× 24 0.4× 19 490
Bernard A. Ruether Canada 14 135 1.0× 130 1.1× 172 1.9× 65 0.9× 73 1.1× 21 519
West Wh United States 10 165 1.3× 39 0.3× 168 1.8× 20 0.3× 32 0.5× 12 390
Annunziata Manna Italy 10 174 1.3× 59 0.5× 138 1.5× 52 0.7× 98 1.4× 29 485
Kyoko Kobuke Japan 4 70 0.5× 108 0.9× 63 0.7× 163 2.3× 16 0.2× 11 371
Juergen H. Bertram United States 11 42 0.3× 58 0.5× 154 1.7× 50 0.7× 40 0.6× 14 357

Countries citing papers authored by M Weil

Since Specialization
Citations

This map shows the geographic impact of M Weil's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M Weil with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M Weil more than expected).

Fields of papers citing papers by M Weil

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M Weil. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M Weil. The network helps show where M Weil may publish in the future.

Co-authorship network of co-authors of M Weil

This figure shows the co-authorship network connecting the top 25 collaborators of M Weil. A scholar is included among the top collaborators of M Weil based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M Weil. M Weil is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Buthiau, D., et al.. (1996). The clinical measurement of volumes using helical CT. Surgical and Radiologic Anatomy. 18(3). 227–231. 4 indexed citations
2.
Soubrane, C., Roger Mouawad, Olivier Rixe, et al.. (1996). Direct gene transfer of a plasmid carrying the Herpes Simplex Virus-thymidine kinase gene (HSV-TK) in transplanted murine melanoma: In vivo study. European Journal of Cancer. 32(4). 691–695. 10 indexed citations
3.
Rixe, Olivier, E. Vuillemin, A. Benhammouda, et al.. (1995). A Phase II Study of Tamoxifen Combined with Cisplatin-Interleukin 2 and Alpha-Interferon in Metastatic Melanoma. American Journal of Clinical Oncology. 18(5). 421–424. 6 indexed citations
4.
Rixe, Olivier, Christian Borel, D. Paraïso, et al.. (1995). Fotemustine, dacarbazine, vindesine combination chemotherapy in advanced malignant melanoma. Melanoma Research. 5(6). 419–424. 10 indexed citations
5.
Mouawad, Roger, Olivier Rixe, A. Benhammouda, et al.. (1994). Study of IL-2 receptor expression after chemoimmunotherapy in patients treated for metastatic malignant melanoma. Clinical & Experimental Immunology. 97(3). 342–346. 6 indexed citations
6.
Weil, M, Matthew R. Smith, & D. Khayat. (1994). Truth‐telling to cancer patients in the western european context. Psycho-Oncology. 3(1). 21–26. 18 indexed citations
7.
Khayat, D., Jean-Pierre Bizzari, Karl Reinhard Aigner, et al.. (1991). Fotemustine (S 10036) in the Intra-Arterial Treatment of Liver Metastasis from Malignant Melanoma. American Journal of Clinical Oncology. 14(5). 400–404. 13 indexed citations
8.
Khayat, D., C. Soubrane, J.M. Andrieu, et al.. (1990). Changes of Soluble CD16 Levels in Serum of HIV-Infected Patients: Correlation with Clinical and Biologic Prognostic Factors. The Journal of Infectious Diseases. 161(3). 430–435. 39 indexed citations
9.
Jacquillat, C, David Khayat, Pierre Banzet, et al.. (1990). Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma. Cancer Chemotherapy and Pharmacology. 25(4). 263–266. 52 indexed citations
10.
Khayat, D., M Weil, C. Soubrane, & C Jacquillat. (1988). [LAK cells and immunotherapy of cancer].. PubMed. 75(1). 3–7. 2 indexed citations
11.
Khayat, D., François Lokiec, Jean-Pierre Bizzari, et al.. (1987). Phase I clinical study of the new amino acid-linked nitrosourea, S 10036, administered on a weekly schedule.. PubMed. 47(24 Pt 1). 6782–5. 47 indexed citations
12.
Sellami, Moncef, M Weil, P Dhermy, D Aron-Rosa, & C Jacquillat. (1986). Adjuvant Chemotherapy in Ocular Malignant Melanoma. Oncology. 43(4). 221–223. 6 indexed citations
13.
Brasnu, Daniel, et al.. (1986). Short-term results of the combination of cis-platinum, 5-fluorouracil and bleomycin in advanced upper aerodigestive tract cancers.. PubMed. 12(1-3). 211–7.
14.
Boiron, M, C Jacquillat, Marion Marty, M Weil, & Christian Gisselbrecht. (1981). Anthracyclines in the treatment of acute nonlymphocytic leukemias.. PubMed. 65 Suppl 4. 73–6. 5 indexed citations
15.
Auclerc, G, et al.. (1981). [Hodgkin's disease: characteristics and prognosis of forms with initial bone marrow involvement (author's transl)].. PubMed. 10(2). 95–100. 4 indexed citations
16.
Jacquillat, C, et al.. (1976). [Prognostic factors in chronic myeloid leukemia. Apropos of 798 cases].. PubMed. 126(6-7). 515–20. 1 indexed citations
17.
Jacquillat, C, et al.. (1975). [New data about oligoblastic leukemias. Apropos of an analysis of 120 cases].. PubMed. 4(13). 947–52. 3 indexed citations
18.
Weil, M, et al.. (1967). [A new antibiotic with antineoplastic activity: rubidomycin (13.057 R.P.)].. PubMed. 17(8). 955–9. 2 indexed citations
19.
Tanzer, J, M Boiron, C Jacquillat, et al.. (1967). [Effects of rubidomycin in chronic myeloid leukemia].. PubMed. 15(19). 943–4. 1 indexed citations
20.
Tanzer, J, C Jacquillat, M Weil, et al.. (1966). [Effects of hydroxyurea in chronic myeloid leukemia. Preliminary study].. PubMed. 74(56). 2929–30. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026